Recursion Pharmaceuticals (RXRX) News Today $6.52 -0.28 (-4.05%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Cathie Wood’s ARK Investment buys 161K shares of Recursion Pharmaceuticals todayMarch 21, 2025 | markets.businessinsider.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 17.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor oMarch 21, 2025 | marketbeat.comPrivium Fund Management B.V. Purchases 41,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Privium Fund Management B.V. raised its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 52.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 119,000 shares of the company's stock after purchasing an additioMarch 20, 2025 | marketbeat.comPlatinum Investment Management Ltd. Acquires 546,929 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Platinum Investment Management Ltd. lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 293.9% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 733,011 shares of the company's stock after purcMarch 20, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down - Time to Sell?March 19, 2025 | marketbeat.comRecursion appoints Namandje Bumpus, Elaine Sun to boardMarch 18, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity OfferingMarch 18, 2025 | finance.yahoo.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 4.5% - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.5% - Time to Buy?March 18, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Nikko Asset Management Americas Inc.Nikko Asset Management Americas Inc. cut its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 8.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,908,651 shares of theMarch 18, 2025 | marketbeat.com6RXRX : Recursion Pharmaceuticals's Options: A Look at...March 17, 2025 | benzinga.comBank of New York Mellon Corp Has $5.75 Million Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Bank of New York Mellon Corp lessened its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 8.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 850,636 shares of the company's stock afterMarch 17, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.6% - Still a Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.6% - What's Next?March 14, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.2% - Time to Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.2% - Should You Sell?March 13, 2025 | marketbeat.comRecursion Pharmaceuticals: Stretched Thin And Chasing UnicornsMarch 12, 2025 | seekingalpha.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.3% - Here's What HappenedRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.3% - Here's What HappenedMarch 12, 2025 | marketbeat.comJim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’March 12, 2025 | insidermonkey.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1.1% - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.1% - Here's WhyMarch 11, 2025 | marketbeat.comCathie Wood’s ARK Investment buys 35K shares of Recursion Pharmaceuticals todayMarch 11, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 6.9% - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 6.9% - Should You Sell?March 10, 2025 | marketbeat.comWhy Recursion Pharmaceuticals Stock Is Sinking TodayMarch 10, 2025 | fool.comApril 25th Options Now Available For Recursion Pharmaceuticals (RXRX)March 8, 2025 | nasdaq.comIs This Beaten-Down Artificial Intelligence (AI) Stock a Buy?March 8, 2025 | fool.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 2.1% - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 2.1% - Should You Buy?March 7, 2025 | marketbeat.com4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock TodayMarch 7, 2025 | fool.comThis Biotech Stock Could Be the Best Investment of the DecadeMarch 7, 2025 | fool.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 1.4% - Time to Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 1.4% Higher - What's Next?March 6, 2025 | marketbeat.comVestmark Advisory Solutions Inc. Has $5.71 Million Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Vestmark Advisory Solutions Inc. increased its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 15.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 845,154 shares of the company's stoMarch 6, 2025 | marketbeat.comDown Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?March 6, 2025 | fool.com49,273 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Purchased by SBI Securities Co. Ltd.SBI Securities Co. Ltd. acquired a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 49,273 shares of the company'sMarch 6, 2025 | marketbeat.comNews Flash: Analysts Just Made A Sizeable Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ForecastsMarch 6, 2025 | finance.yahoo.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.3% Higher - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 0.3% - What's Next?March 5, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.1% - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.1% - Here's WhyMarch 4, 2025 | marketbeat.comRecursion Pharmaceuticals (NasdaqGS:RXRX) Surges 6% Following US$500 Million Follow-On Equity OfferingMarch 4, 2025 | finance.yahoo.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.3% Following Weak EarningsRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.3% on Disappointing EarningsMarch 3, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call TranscriptMarch 3, 2025 | insidermonkey.comRecursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The DipMarch 3, 2025 | msn.comRecursion Pharmaceuticals (RXRX) Gets a Hold from TD CowenMarch 1, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Price Target Lowered to $6.00 at Leerink PartnersLeerink Partners lowered their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday.March 1, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Given New $6.00 Price Target at Leerink PartnersLeerink Partners lowered their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research note on Friday.February 28, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Releases Quarterly Earnings Results, Misses Estimates By $0.17 EPSRecursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $4.60 million during the quarter, compared to analysts' expectations of $19.04 million. During the same quarter in the previous year, the firm earned ($0.42) earnings per share. Recursion Pharmaceuticals's revenue was down 57.8% on a year-over-year basis.February 28, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Issues Quarterly Earnings ResultsRecursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) issued its earnings results on Friday. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals's quarterly revenue was down 57.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.42) earnings per share.February 28, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comRecursion Pharmaceuticals misses Q4 estimates, shares dipFebruary 28, 2025 | in.investing.comRecursion Pharmaceuticals price target lowered to $6 from $7 at LeerinkFebruary 28, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.8% on Disappointing EarningsRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.8% After Earnings MissFebruary 28, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down Following Weak EarningsRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down After Earnings MissFebruary 28, 2025 | marketbeat.comRecursion Pharmaceuticals reports Q4 EPS (53c) vs. (42c) last yearFebruary 28, 2025 | markets.businessinsider.comRecursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsFebruary 28, 2025 | globenewswire.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.3% - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.3% - Here's What HappenedFebruary 27, 2025 | marketbeat.comCathie Wood’s ARK Investment buys 103K shares of Recursion Pharmaceuticals todayFebruary 27, 2025 | markets.businessinsider.com Remove Ads Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address RXRX Media Mentions By Week RXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RXRX News Sentiment▼0.840.63▲Average Medical News Sentiment RXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RXRX Articles This Week▼98▲RXRX Articles Average Week Remove Ads Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ascendis Pharma A/S News Today Vaxcyte News Today Qiagen News Today Roivant Sciences News Today Sarepta Therapeutics News Today Revolution Medicines News Today BridgeBio Pharma News Today Lantheus News Today TG Therapeutics News Today Legend Biotech News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RXRX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RXRX Stock Free RXRX Stock Alerts